Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients

Table 3 Subgroup analysis according to the type of thyroid dysfunction

	No thyroid irAE (N = 127)	Thyroid irAE (N = 58)
	No thyroid irAE (N = 127)	Newly developed overt hypothyroidism (N = 38)	Worsened hypothyroidism (N = 4)	Subclinical hyperthyroidism (N = 16)	P value
Age (years) ^a	64.1 ± 11.2	65.0 ± 12.6	70.0 ± 8.8	69.9 ± 6.3	0.191
Male, n (%)	91 (71.7%)	31 (81.6%)	1 (25%)	12 (75%)	0.1003
Death, n (%)	64 (50.4%)	11 (28.9%)	2 (50%)	6 (37.5%)	0.119
Treatment time ^b (month)	4.0 ± 6.8	8.9 ± 8.0	11.0 ± 7.6	4.7 ± 7.1	0.001
Period from initiation of ICI treatment to death (month)	9.7 ± 10.0	15.4 ± 10.9	15.0 ± 11.9	12.0 ± 10.9	0.025
Period from initiation of ICI treatment to diagnosis of irAE (month)	9.7 ± 10.0^c	3.9 ± 5.3	1.0 ± 0.8	2.3 ± 5.7	< 0.001

irAE immune related Adverse Event, BMI Body Mass Index, HCC Hepatocellular Carcinoma, ICI Immune check point Inhibitor
^aAge at ICI initiation
^bthe time from ICI treatment initiation date to last ICI treatment date
^cIt is same as period from initiation of ICI treatment to death or last follow up because thyroid irAE did not occur

ISSN: 1472-6823